Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)

Prelude Therapeutics (PRLD) posted Current Deferred Revenue of $31.0 million for Q1 2026, down 8.25% sequentially from $33.7 million in Q4 2025.

Analysis

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $31.0 million in Q1 2026.

Quarterly Current Deferred Revenue changed N/A year-over-year to $31.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.0 million (changed N/A YoY) and the FY2025 annual result came in at $33.7 million, changed N/A from the prior year.
Current Deferred Revenue declined to $31.0 million in Q1 2026 per PRLD's latest filing, from $33.7 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $33.7 million in Q4 2025 and troughed at $3.0 million in Q2 2024.
A 3-year average of $22.6 million and a median of $31.0 million in 2026 frame the typical range for Current Deferred Revenue.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Prelude Therapeutics	539.17 Mn	258.54 Mn	-

Historic Data

Download Data